Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PKLR | P30613 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 16/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286223 | 0.92 | PKM (0.53) | PKMPKLRRORC | |
| SCHEMBL24286545 | 0.91 | RORC (0.62) | PKMPKLRRORCCYP11B1CYP11B2 | |
| SCHEMBL24286390 | 0.91 | PKM (0.57) | PKMPKLRRORCKMT2APAX8 | |
| SCHEMBL24286566 | 0.90 | RORC (0.57) | PKMPKLRRORCKMT2APAX8 | |
| SCHEMBL24286476 | 0.90 | PKM (0.55) | PKMPKLRRORCKMT2APAX8 | |
| SCHEMBL24287078 | 0.90 | RORC (0.56) | PKMPKLRRORCCYP11B1CYP11B2 | |
| SCHEMBL24286198 | 0.90 | RORC (0.63) | PKMPKLRRORCCYP11B1CYP11B2 | |
| SCHEMBL24286832 | 0.89 | PKM (0.50) | PKMPKLRRORCKMT2APAX8 | |
| SCHEMBL24286707 | 0.89 | RORC (0.55) | PKMPKLRRORC | |
| SCHEMBL24286486 | 0.88 | RORC (0.64) | PKMPKLRRORCKMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |